Ginecologia/Obstetrícia

Revisão abrangente de revisões sistemáticas | Exposições pré-concepção e desfechos adversos em gestação, parto e pós-parto.

28 Jan, 2022 | 15:58h

Preconception exposures and adverse pregnancy, birth and postpartum outcomes: Umbrella review of systematic reviews – Paediatric and Perinatal Epidemiology

Opinião | “O uso de escores de risco poligênico em testes de pré-implantação genética: uma prática não provada e antiética.”

28 Jan, 2022 | 15:27h

The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice – European Journal of Human Genetics

Comentário: ‘Unproven and unethical’: experts warn against genetic embryo tests – The Guardian

Estudo randomizado | Ertapenem 1.000 mg em dose única é não inferior a ceftriaxona 500 mg em dose única para o tratamento da gonorreia.

25 Jan, 2022 | 14:48h

Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial – The Lancet Infectious Diseases (link para o resumo – $ para o texto completo)

Comentário no Twitter (fio – clique para saber mais)

New from @TheLancetInfDis Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial by @henryjdevries and colleagues https://t.co/K2fw5ORNlm pic.twitter.com/d8wz1Vc41Q

— The Lancet HIV (@TheLancetHIV) January 24, 2022

Estudo randomizado | Gel de ácido lático vs. metronidazol para vaginose bacteriana recorrente em mulheres de 16 anos de idade ou mais.

25 Jan, 2022 | 11:41h

Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT – Health Technology Assessment

Estudo MINDACT | Desfecho de pacientes com câncer de mama com risco ultrabaixo em painel genético.

25 Jan, 2022 | 11:36h

Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)

Conteúdos relacionados:

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer – New England Journal of Medicine

Comentário no Twitter:

In MINDACT, 15% of the pts (n=1000) had an ultra-low 70-gene signature. Although some had tumors >2 cm (20%) & were LN+ (20%), prognosis was outstanding

8-year DMFI 97%
8-year BCSS 99.6%

Most of these patients received adj treatment. Did they need it?https://t.co/V9SH2StuQE

— Paolo Tarantino (@PTarantinoMD) January 22, 2022

Guia prático: tratamento da síndrome da bexiga dolorosa.

25 Jan, 2022 | 11:27h

Management of Bladder Pain Syndrome (BPS): A Practical Guide – Advances in Urology

Sistema de estratificação de risco por imagem O-RADS: guia do ACR O-RADS Committee para avaliação de lesões anexiais.

20 Jan, 2022 | 22:53h

O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee – Radiology

Uso de bisfosfonatos adjuvantes e outros agentes modificadores ósseos no câncer de mama: atualização da diretriz ASCO-OH (CCO).

20 Jan, 2022 | 22:52h

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update – Journal of Clinical Oncology

Comentário no Twitter

Out on @JCO_ASCO the new ASCO/OH guidelines for adjuvant bisphosphonates in BC

Important to weight risks and benefits based on the risk profile of the disease, financial toxicity, drug availability, patient preferences, comorbidities & life expectancy. https://t.co/6noyYplALB

— Paolo Tarantino (@PTarantinoMD) January 18, 2022

Revisão | Diagnóstico e tratamento da síndrome do ovário policístico.

20 Jan, 2022 | 22:49h

Diagnosis and Treatment of Polycystic Ovary Syndrome – JAMA (gratuito por tempo limitado)

Interrupções no uso de serviços de saúde materna durante a pandemia de COVID-19 em 2020: experiências de 37 instituições de saúde em países de baixa e média rendas.

20 Jan, 2022 | 22:17h

Disruptions in maternal health service use during the COVID-19 pandemic in 2020: experiences from 37 health facilities in low-income and middle-income countries – BMJ Global Health

Comentário de um dos autores no Twitter (fio – clique para saber mais)

Just out: **Effect of COVID-19 pandemic on maternal health services at 37 facilities in six countries** 1/

Have learned and been inspired by this collaboration including: @PIH @GHResearchCore @HMSghsm @jcmugunga @isabelfulcher @megan_b_murray https://t.co/nKIRhJS2Jm pic.twitter.com/uOkyuNRA1w

— Bethany Hedt-Gauthier, PhD (@BHedtGauthier) January 10, 2022